An estimated 589 million adults live with diabetes globally, shifting focus toward oral daily medications that bypass the need for weekly injections and complex cold-chain storage infrastructure.
The global management of diabetes and obesity is undergoing a substantial therapeutic evolution. As reported, medications belonging to the glucagon-like peptide-1 receptor agonist class are transitioning from weekly subcutaneous injections into daily oral tablets, promising to expand access in developing regions where healthcare systems face severe logistical hurdles.
In Plain English: The Clinical Takeaway
- GLP-1 mechanism of action: These medications mimic a natural hormone called glucagon-like peptide-1, which signals the pancreas to release insulin when blood sugar levels rise, slows down how fast the stomach empties, and reduces the feeling of hunger.
- Supply chain transformation: Shifting from injectables to pills can eliminate the same cold-chain requirements as injectable preparations, making distribution easier in areas with limited medical infrastructure.
- Clinical targets: The therapies are designed for regulating type 2 diabetes and reducing body weight, though they require medical guidance and do not replace a healthy lifestyle.
Diabetes Prevalence and Challenges in the Global South
According to data from the International Diabetes Federation, roughly one in nine adults between the ages of 20 and 79 are managing diabetes worldwide. The disease represents a growing problem in the Global South, where high costs and limited healthcare facilities complicate care.
Suriname faces a high rate of disease. IDF figures for 2024 indicate that approximately 53,200 adults live with diabetes in the country, translating to an estimated adult prevalence rate of 13.8 percent.
Established injectable treatments like semaglutide—marketed as Ozempic and Wegovy—along with tirzepatide, known as Mounjaro, have driven the recent therapeutic shift. However, their reliance on weekly administration creates distribution challenges that daily oral formulations aim to solve.
Regulatory Approvals and Global Rollouts
Regulatory milestones for oral GLP-1 therapies have accumulated. In December 2025, the U.S. Food and Drug Administration approved a tablet form of semaglutide under the brand name Wegovy for weight management in adults with obesity or overweight linked to weight-related health conditions.
On April 1, 2026, the FDA approved Foundayo, an oral daily pill containing orforglipron developed by Eli Lilly, for weight management in adults with obesity or overweight alongside at least one related condition. Unlike oral semaglutide, for which specific intake guidelines apply, orforglipron can be taken at any time of day without having to account for food or water restrictions.
International approvals followed as the year progressed. On October 15, the European Medicines Agency issued positive advice regarding Foundayo, moving the drug closer to market authorization in the European Union. On November 12, 2026, Eli Lilly secured approval from Chinese authorities for orforglipron, making the company the first manufacturer to gain authorization for an oral GLP-1 weight-loss treatment in China.
| Drug Name | Developer | Key Regulatory Milestone | Dosing Requirements |
|---|---|---|---|
| Wegovy (oral semaglutide) | FDA Approval (December 2025) | Specific intake guidelines apply | |
| Foundayo (orforglipron) | Eli Lilly | FDA Approval (April 1, 2026) / China Approval (November 12, 2026) | Taken at any time without food or water restrictions |
Affordability Obstacles and Public Health Guidance
Despite these clinical advancements, cost remains a primary barrier to patient access. Injectable GLP-1 drugs are expensive in many countries and are not always reimbursed by insurance or health programs.
In the Global South, the availability of locally produced tablet formulations could eventually make a difference compared to imported medicines. Yet, lower production costs do not guarantee universal access, as local drug registration, production capacity, and the financial possibilities of healthcare systems heavily influence distribution.
In December 2025, the World Health Organization published guidelines conditionally recommending GLP-1 medications as a long-term treatment for adults with obesity. At the same time, the agency emphasized that high costs and limited availability remain important concerns, advocating for pooled procurement, differentiated pricing, and voluntary licensing agreements.
Counterfeit Risks and Illicit Markets
The growing popularity of GLP-1 drugs has brought risks. People are increasingly using these medications for weight loss without a medical indication or guidance from a doctor.
In July 2026, the WHO issued a warning regarding obtaining these medicines through unregulated internet sellers and other unofficial channels. Counterfeit products and preparations where composition or dosage cannot be reliably determined can pose serious health risks.
The Pan American Health Organization also called for stricter control on the distribution and use of these medicines in the Americas, emphasizing that GLP-1 medications should only be used on medical indication and under the guidance of qualified healthcare personnel.
Factors Affecting Oral GLP-1 Tablet Impact
The ultimate impact of oral GLP-1 tablets on millions of people in developing countries will depend on price, availability, and the capacity of national healthcare systems to offer the medicines safely.
References
- IDF Diabetes Atlas.
- Richtlijnen over het langetermijngebruik van GLP-1-receptoragonisten bij obesitasbeheer.
